Company Profile

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE615.151.85 (+0.3 % )
PREV CLOSE (Rs.) 613.30
OPEN PRICE (Rs.) 618.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 54985
TODAY'S LOW / HIGH (Rs.)611.80 619.35
52 WK LOW / HIGH (Rs.)100.8 641.95
NSE614.85 1.3 (+0.21 % )
PREV CLOSE(Rs.) 613.55
OPEN PRICE (Rs.) 618.30
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 614.85 (152 )
VOLUME 1250174
TODAY'S LOW / HIGH(Rs.) 611.40 619.70
52 WK LOW / HIGH (Rs.)101.02 641.65

Company News

Date Heading Details
30-Apr-2021 Laurus Labs reports around 3-fold jump in Q4 consolidated net profit <p align="justify">Laurus Labs has reported results for fourth quarter and year ended March 31, 2021.<p align="justify">The company has reported around 3-fold jump in its net profit at Rs 292.78 crore for the quarter under review as compared to Rs 112.53 crore for the same quarter in the previous year. Total income of the company increased by 69.04% at Rs 1,404.46 crore for Q4FY21 as compared Rs 830.85 crore for the corresponding quarter previous year.<p align="justify">On the consolidated basis, the company has reported around 3-fold jump in its net profit attributed to the owners at Rs 296.68 crore for the quarter under review as compared to Rs 110.15 crore for the same quarter in the previous year. Total income of the company increased by 68.46% at Rs 1,416.45 crore for Q4FY21 as compared Rs 840.82 crore for the corresponding quarter previous year.<p align="justify">For the year ended March 31, 2021, the company has reported around 4-fold jump in its net profit at Rs 956.11 crore as compared to Rs 267.05 crore for the previous year. Total income of the company increased by 71.09% at Rs 4,796.04 crore for year under review as compared to Rs 2,803.15 crore for year ended March 31, 2020.<p align="justify">For the year ended March 31, 2021, on the consolidated basis, the company has reported around 4-fold jump in its net profit attributed to the owners at Rs 983.58 crore as compared to Rs 255.27 crore for the previous year. Total income of the company increased by 70.46% at Rs 4,837.17 crore for year under review as compared to Rs 2,837.64 crore for year ended March 31, 2020.</p>
30-Apr-2021 Laurus Labs rises on reporting around 3-fold jump in Q4 consolidated net profit <p align="justify">Laurus Labs is currently trading at Rs. 460.25, up by 2.20 points or 0.48% from its previous closing of Rs. 458.05 on the BSE.<p align="justify">The scrip opened at Rs. 458.05 and has touched a high and low of Rs. 466.50 and Rs. 451.30 respectively. So far 75173 shares were traded on the counter.<p align="justify">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 482.65 on 29-Apr-2021 and a 52 week low of Rs. 84.40 on 18-May-2020.<p align="justify">Last one week high and low of the scrip stood at Rs. 482.65 and Rs. 450.65 respectively. The current market cap of the company is Rs. 24850.06 crore.<p align="justify">The promoters holding in the company stood at 27.45%, while Institutions and Non-Institutions held 24.24% and 48.31% respectively.<p align="justify">Laurus Labs has reported around 3-fold jump in its net profit at Rs 292.78 crore for fourth quarter ended March 31, 2021 as compared to Rs 112.53 crore for the same quarter in the previous year. Total income of the company increased by 69.04% at Rs 1,404.46 crore for Q4FY21 as compared Rs 830.85 crore for the corresponding quarter previous year.<p align="justify">On the consolidated basis, the company has reported around 3-fold jump in its net profit attributed to the owners at Rs 296.68 crore for fourth quarter ended March 31, 2021 as compared to Rs 110.15 crore for the same quarter in the previous year. Total income of the company increased by 68.46% at Rs 1,416.45 crore for Q4FY21 as compared Rs 840.82 crore for the corresponding quarter previous year.<p align="justify">For the year ended March 31, 2021, the company has reported around 4-fold jump in its net profit at Rs 956.11 crore as compared to Rs 267.05 crore for the previous year. Total income of the company increased by 71.09% at Rs 4,796.04 crore for year under review as compared to Rs 2,803.15 crore for year ended March 31, 2020.<p align="justify">For the year ended March 31, 2021, on the consolidated basis, the company has reported around 4-fold jump in its net profit attributed to the owners at Rs 983.58 crore as compared to Rs 255.27 crore for the previous year. Total income of the company increased by 70.46% at Rs 4,837.17 crore for year under review as compared to Rs 2,837.64 crore for year ended March 31, 2020.</p>
29-Apr-2021 Laurus Labs board approves interim dividend payment <p align="justify">Laurus Labs has informed that the Board of Directors of the Company in their meeting held on April 29, 2021 have approved for the payment of 3rd interim dividend of 80 Paise (40%) per equity share of Rs 2 each, for the Financial Year 2020-21. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed May 12, 2021 as Record Date for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 19, 2021. The Board Meeting commenced at 1.30 PM and concluded at 2.30 PM.</p><p align="justify">The above information is a part of company's filings submitted to BSE.</p>
29-Apr-2021 Laurus Labs informs about investor presentation <p align="justify">Laurus Labs has informed that it has enclosed the presentation to the Investors/ Analysts on the Standalone and Consolidated Financial Results of the Company for the Quarter and year ended March 31, 2021, for the Investors/ Analysts call scheduled on April 30, 2021, which was already intimated on April 26, 2021. The presentation is also being uploaded on the website of the Company www.lauruslabs.com.</p><p align="justify">The above information is a part of company's filings submitted to BSE.</p>
29-Apr-2021 Board declares Third Interim Dividend (AGM on July 15, 2021) Laurus Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 29, 2021, inter alia, has approved for the payment of 3rd interim dividend of 80 Paise (40%) per equity share of Rs. 2/- each, for the Financial Year 2020-21.
29-Apr-2021 Book Closure For AGM F.Y 2021 Intimation of Book Closure pursuant to Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
29-Apr-2021 Allotment of Equity shares under ESOP Inter alia, approved the following: 1. Approved for the payment of 3rd interim dividend of80 Paise (40?/o) per equity share ofRs.2/- each, for the Financial Year 2020-21. 2. Re-appointment of Mrs. Aruna Rajendra Bhinge as an Independent Director for second term ( 4) Re-appointment of Dr. Rajesh Koshy Chandy as an Independent Director for second term Recommended to the shareholders, the re-appointment of Dr. Rajesh Koshy Chancly as an Independent Director for a further term period of five years (second term) with effect from July 27, 2021. (5) ESOP Scheme 2021 Recommended to the shareholders for the approval of ESOP Scheme 2021 of the Company, to create, offer, issue and allot at any time to or for the benefit of such person(s) who are in the employment of the Company, including Directors of the Company whether whole time or otherwise whether working in India or out of India, under a Scheme titled "LAURUS LABS EMPLOYEE STOCK OPTION SCHEME 2021" (hereinafter referred as the "ESOP Scheme, 2021" or "Scheme"), options exercisable into equity shares being not more than 1,000,000 (One Million Only) equity shares of Rs.2 each of the Company at an exercise price of 25% discount on the Fair Market Value of Share on the date of Grant of Options under ESOP Scheme 2021, in one or more tranches and on such terms and conditions as may be fixed or determined by the Board/Committee in accordance with the provisions of the Companies Act 2013 or SBEB Regulations or other provisions of the laws as may be prevailing and applicable at that time, each option granted being exercisable for one equity share of the Company." (6) 16th Annual General Meeting of the Company Approved the Notice for convening the 16th Annual General Meeting (AGNI) of the Company on July 15, 2021 at 03.00 PM (IST) through Video Conference and Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from July 09, 2021 to July 15, 2021 (both days inclusive) for taking record of the Members of the Company for the purpose of 16th Annual General Nleeting.
26-Apr-2021 Laurus Labs informs about conference call <p align="justify">Laurus Labs has informed that it is a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Friday, April 30, 2021 at 11:00 am IST. The conference call will be initiated with a brief management discussion on the Q4 &amp; FY21 results, followed by an interactive Question &amp; Answer session. The call will be hosted by Ambit Capital. Details of the conference call are enclosed.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
07-Apr-2021 Laurus Labs informs about compliance certificate <div><span>Laurus Labs has informed that it has enclosed certificate under regulation 74(5) of SEBI (DP) Regulations, 2018.</span></div><div><font face="sans-serif"><span><br></span></font></div><div><font face="sans-serif"><span>The above information is a part of company's filings submitted to BSE.</span></font></div><div><br></div>
13-Mar-2021 Laurus Labs submits disclosure <p align="justify">Laurus Labs has submitted disclosure.<br></p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>